The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
Open accessAbstract
The messenger RNA vaccine BNT162b2 (Pfizer–BioNTech) has 95% efficacy against coronavirus disease 2019 (Covid-19). Qatar launched a mass immunization campaign with this vaccine on December 21, 2020. As of March 31, 2021, a total of 385,853 persons had received at least one vaccine dose and 265,410 had completed the two doses. Vaccination scale-up occurred as Qatar was undergoing its second and third waves of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which were triggered by expansion of the B.1.1.7 variant (starting in mid-January 2021) and the B.1.351 variant (starting in mid-February 2021). The B.1.1.7 wave peaked during the first week of March, and the rapid expansion of B.1.351 started in mid-March and continues to the present day. Viral genome sequencing conducted from February 23 through March 18 indicated that 50.0% of cases of Covid-19 in Qatar were caused by B.1.351 and 44.5% were caused by B.1.1.7. Nearly all cases in which virus was sequenced after March 7 were caused by either B.1.351 or B.1.1.7.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The test-negative design, which does not assume that a lack of a positive test equals a negative test and somewhat adjusts for testing volume, attempts to better mitigate this bias and is the reason we chose this method for this analysis”
From Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine (2022) · cites this paper as [25]
In the citing paper
“Reduced protection against any symptomatic COVID-19 disease caused by the B.1.351 variant of concern (now known as the Beta variant) has been reported from clinical trials18, but emerging data suggest that there remains high protection against the important end points of severe disease and hospitalization99.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [99]
In the citing paper
“These inclusion and exclusion criteria were implemented to allow for build-up of immunity after vaccination4,14 and to minimize different types of potential bias, as informed by earlier analyses in the same population.”
From Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections (2022) · cites this paper as [14]
In the citing paper
“Effectiveness was assessed with the use of an observational, test-negative, case–control design rather than a design in which cohorts of individual persons were followed up. However, the cohort study design applied earlier to the same population yielded findings similar to those of the test-negative design.14,15,31”
From Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections (2022) · cites this paper as [14]
In the citing paper
“However, the cohort study design applied earlier to the same population of Qatar yielded findings similar to those of the test-negative case–control design36,38,39, supporting the validity of this standard approach in assessing vaccine effectiveness11,12,36,40.”
From Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar (2022) · cites this paper as [38]
In the citing paper
“As compared with recent findings from Qatar on the effectiveness of the BNT162b2 vaccine against the alpha and beta variants,17 our findings suggest that effectiveness against the delta variant after a full vaccination course lies somewhere between these two.”
From Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant (2021) · cites this paper as [17]
In the citing paper
“In cohort studies from Israel and Qatar, the BNT162b vaccine also retained greater than 90% efficacy against this variant 210,211 (TABLe 2).”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [211]
In the citing paper
“In the previously cited Qatar cohort study, the efficacy of BNT162b against the Beta variant was estimated to be 72%, which was 15% lower than that for the Alpha variant 211 .”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [211]
In the citing paper
“Likewise, clinical studies have reported somewhat reduced efficacy and effectiveness against the B.1.1.7, B.1.351, and B.1.617.2 variants (10–12).”
From Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants (2021) · cites this paper as [10]
In the citing paper
“The effectiveness of the BNT162b2 vaccine against the Beta variant was measured shortly after the population of Qatar had been vaccinated, whereas the effectiveness of BNT162b2 against the Delta variant was conducted several months after the second dose, which could be one of the reasons for low effectiveness of BNT162b2 against the Delta variant.404,405”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [405]
In the citing paper
“Beta [as a benchmark for partially reduced neutralization (7) without major impact on effectiveness (19, 20)]”
From Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera (2022) · cites this paper as [19]
In the citing paper
“Coronavirus disease 2019 (Covid-19) vaccines are highly effective against symptomatic disease and, more so, against severe disease and fatal outcomes caused by the original strain of SARS-CoV-2 as well as the alpha (B.1.1.7) variant that predominated in early 2021.”
From Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern (2021) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527
Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H. L., Yoon, S. K., Meece, J., Olsho, L. E. W., Caban-Martinez, A. J., Fowlkes, A., Lutrick, K., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7013e3 · Cited by 707
The test-negative design for estimating influenza vaccine effectiveness
Jackson, M. L., & Nelson, J. C. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.02.053 · Cited by 510
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 879
Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus
Amanat, F., Strohmeier, S., Meade, P. S., Dambrauskas, N., Mühlemann, B., Smith, D. J., Vigdorovich, V. I., Sather, D. N., Coughlan, L., & Krammer, F. (2021) · PLoS Biology · doi:10.1371/journal.pbio.3001384 · Cited by 20
Li, R., Li, Y., Zou, Z., Liu, Y., Li, X., Zhuang, G., Shen, M., & Zhang, L. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2021.801763 · Cited by 20
SARS-CoV-2–Specific Vaccine Candidates; the Contribution of Structural Vaccinology
Pack, S. M., & Peters, P. J. (2022) · Vaccines · doi:10.3390/vaccines10020236 · Cited by 19
Anguzu, R., Kabagenyi, A., Cassidy, L. D., Kasasa, S., Shour, A. R., Musoke, B. N., & Nankya-Mutyoba, J. (2022) · PLOS Global Public Health · doi:10.1371/journal.pgph.0000177 · Cited by 19
Emerging issues related to COVID-19 vaccination in patients with cancer
Saini, K. S., Martins-Branco, D. A., Tagliamento, M., Vidal, L., Singh, N., Punie, K., Saini, M. L., Chico, I. M., Curigliano, G., de Azambuja, E., et al. (2021) · Oncology and Therapy · doi:10.1007/s40487-021-00157-1 · Cited by 19
Meggiolaro, A., Schepisi, M. S., Nikolaidis, G., Mipatrini, D., Siddu, A., & Rezza, G. (2022) · Vaccines · doi:10.3390/vaccines10020157 · Cited by 19
Hammad, W. A. B., Beloushi, M. A., Ahmed, B., & Konje, J. C. (2021) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2021.06.001 · Cited by 22
A reasoned approach towards administering COVID‐19 vaccines to pregnant women
Pramanick, A., Kanneganti, A., Wong, J. L. J., Li, S. W., Dimri, P. S., Mahyuddin, A. P., Kumar, S., Illanes, S. E., Chan, J. K. Y., Su, L., et al. (2021) · Prenatal Diagnosis · doi:10.1002/pd.5985 · Cited by 19
Pépin, J., Labbé, A., Carignan, A., Parent, M., Yu, J. W., Grenier, C., Beauchemin, S., Wals, P. D., Valiquette, L., & Rousseau, M. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.08.019 · Cited by 18
Kongsomros, S., Suksatu, A., Kanjanasirirat, P., Manopwisedjaroen, S., Prasongtanakij, S., Jearawuttanakul, K., Borwornpinyo, S., Hongeng, S., Thitithanyanont, A., & Chutipongtanate, S. (2021) · Biomedicines · doi:10.3390/biomedicines9091230 · Cited by 18
Boosters reduce in-hospital mortality in patients with COVID-19: An observational cohort analysis
Mielke, N., Johnson, S., & Bahl, A. (2022) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2022.100227 · Cited by 18
Epidemiological characteristics of the B.1.526 SARS-CoV-2 variant
Yang, W., Greene, S. K., Peterson, E. R., Li, W., Mathes, R. W., Graf, L. E., Lall, R., Hughes, S., Wang, J., & Fine, A. D. (2022) · Science Advances · doi:10.1126/sciadv.abm0300 · Cited by 18
Melton, A., Doyle‐Meyers, L. A., Blair, R. V., Midkiff, C. C., Melton, H. J., Russell‐Lodrigue, K., Aye, P. P., Schiro, F. R., Fahlberg, M. D., Szeltner, D. M., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1010162 · Cited by 19
Clemens, J. D., Aziz, A. B., Tadesse, B. T., Kang, S. S. Y., Marks, F., & Kim, J. H. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101253 · Cited by 17
Mostafa, H. H., Luo, C. H., Morris, C. P., Li, M., Swanson, N. J., Amadi, A., Gallagher, N., & Pekosz, A. S. (2022) · Journal of Clinical Virology · doi:10.1016/j.jcv.2022.105151 · Cited by 18
Ibarrondo, F. J., Hofmann, C., Ali, A., Ayoub, P., Kohn, D. B., & Yang, O. O. (2021) · mBio · doi:10.1128/mbio.02656-21 · Cited by 17
Sukik, L., Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Yassine, H. M., Thani, A. A. A., Hasan, M. R., Kanaani, Z. A., Al‐Kuwari, E., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.04.026 · Cited by 17
Self-citationJörling, M., Eitze, S., Schmid, P., Betsch, C., Allen, J., & BOHM, R. M. (2022) · Information Communication & Society · doi:10.1080/1369118x.2022.2050418 · Cited by 17
Zhu, D. Y., Gorman, M. J., Yuan, D., Yu, J., Mercado, N. B., McMahan, K., Borducchi, E. N., Lifton, M. A., Liu, J., Nampanya, F., et al. (2022) · PLoS Biology · doi:10.1371/journal.pbio.3001609 · Cited by 18
Napuri, N., Curcio, D., Swerdlow, D. L., & Srivastava, A. K. (2022) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00648-2 · Cited by 18
Poparn, H., Srichumpuang, C., Sosothikul, D., Jantarabenjakul, W., Lauhasurayotin, S., Techavichit, P., Chiangthong, K., & Poovorawan, Y. (2022) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2022.23.6.2049 · Cited by 17
Esmaeilzadeh, A., Maleki, A. J., Moradi, A., Siahmansouri, A., Barhaghtalab, M. J. Y., Karami, P., & Elahi, R. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2116008 · Cited by 17
Qassim, S. H., Hasan, M. R., Tang, P., Chemaitelly, H. S., Ayoub, H. H., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Rahim, H. F. A., Nasrallah, G. K., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.984784 · Cited by 19
Self-citationChimeric mRNA-based COVID-19 vaccine induces protective immunity against Omicron and Delta variants
Hu, Q., Zhao, Y., Shaabani, N., Lyu, X., Powers, C., Sun, H., Cruz, V., Stegman, K., Xu, J., Fossier, A., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.10.021 · Cited by 17
Kim, D., Keskinocak, P., Pekgün, P., & Yildirim, I. B. (2022) · Scientific Reports · doi:10.1038/s41598-022-11060-8 · Cited by 18
Amanat, F., Strohmeier, S., Lee, W.-H., Bangaru, S., Ward, A. B., Coughlan, L., & Krammer, F. (2021) · mBio · doi:10.1128/mbio.01002-21 · Cited by 16
Analysis of Delayed Vaccination Regimens: A Mathematical Modeling Approach
González‐Parra, G. (2021) · Epidemiologia · doi:10.3390/epidemiologia2030021 · Cited by 16
Immunogenic amino acid motifs and linear epitopes of COVID-19 mRNA vaccines
Wisnewski, A. V., Redlich, C. A., Kamath, K., Abad, Q.-A., Smith, R., Fazen, L. E., Santiago, R., Liu, J., Luna, J. C., Martinez, B., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0252849 · Cited by 16
National survey on deceased donor organ transplantation during the COVID-19 pandemic in Japan
Ito, T., Kenmochi, T., Ota, A., Kuramitsu, K., Soyama, A., Kinoshita, O., Eguchi, S., Yuzawa, K., & Egawa, H. (2021) · Surgery Today · doi:10.1007/s00595-021-02388-1 · Cited by 17
Wong‐Chew, R. M., Ramírez, J. B. D., Carbajal, P. B., León, M. L. G., Angel-Ambrocio, A. H., Velázquez, X. V., Maldonado, L. A. C., González, Y. V., Martínez, L. M. V., Bautista, D. G., et al. (2021) · Acta Médica Grupo Ángeles · doi:10.35366/101742 · Cited by 17
Tarabini, R. F., Rigo, M., Fonseca, A. F., Rubin, F. P., Belle, R. L., Kavraki, L. E., Ferreto, T. C., Antunes, D. A., & de Souza, A. P. D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.812176 · Cited by 16
Hatcher, S. M., Endres‐Dighe, S. M., Angulo, F. J., Srivastava, A. K., Nguyen, J. L., Khan, F. L., Martin, C., Swerdlow, D. L., McLaughlin, J. M., Ubaka-Blackmoore, N., et al. (2022) · Vaccines · doi:10.3390/vaccines10030393 · Cited by 17
Bhattacharya, M., Sharma, A. R., Dhama, K., Agoramoorthy, G., & Chakraborty, C. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108766 · Cited by 17
COVID-19 vaccines: Update of the vaccines in use and under development
Marta, R. A., Nakamura, G. E. K., Aquino, B. D. M., & Bignardi, P. R. (2022) · Vacunas (English Edition) · doi:10.1016/j.vacun.2022.06.003 · Cited by 16
Delshad, M., Sanaei, M., Pourbagheri‐Sigaroodi, A., & Bashash, D. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109128 · Cited by 18
Yakoubi, A., & Dhafer, C. E. B. (2022) · Plasmonics · doi:10.1007/s11468-022-01754-0 · Cited by 16
Pfizer COVID vaccine protects against worrying coronavirus variants
Callaway, E. (2021) · Nature · doi:10.1038/d41586-021-01222-5 · Cited by 16
The impact of COVID-19 on global tuberculosis control
Lipman, M. C. I., McQuaid, C. F., Abubakar, I. I., Khan, M. S., Kranzer, K., McHugh, T. D., Padmapriyadarsini, C., Rangaka, M. X., & Stoker, N. G. (2021) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_326_21 · Cited by 16
Vaccines Against COVID-19: A Review
Torres-Estrella, C. U., Reyes-Montes, M. D. R., Duarte-Escalante, E., Sierra-Martínez, M., León, M. G. F.-D., & Acosta‐Altamirano, G. (2022) · Vaccines · doi:10.3390/vaccines10030414 · Cited by 18
Abou-Saleh, H., Halawa, B. Y. A., Younes, S. N., Younes, N., Al‐Sadeq, D. W., Shurrab, F. M., Liu, N., Qotba, H. A., Al-Dewik, N. I. E., Ismail, A., et al. (2022) · Journal of Travel Medicine · doi:10.1093/jtm/taac130 · Cited by 16
Self-citationEfficacy and Safety of COVID-19 Vaccines—An Update
Sharma, E., Revinipati, S., Bhandari, S., Thakur, S., Goyal, S., Ghose, A., Bajpai, S., Muhammad, W., & Boussios, S. (2022) · Diseases · doi:10.3390/diseases10040112 · Cited by 17
Shoaib, S., Ansari, M. A., Kandasamy, G., Vasudevan, R., Hani, U., Chauhan, W., Alhumaidi, M. S., Altammar, K. A., Azmi, S., Ahmad, W., et al. (2023) · Molecules · doi:10.3390/molecules28020795 · Cited by 15
Safe Surgery During the COVID-19 Pandemic
Singhal, R., Dickerson, L., Sakran, N., Pouwels, S., Chiappetta, S., Weiner, S. R., Purkayastha, S., Madhok, B., & Mahawar, K. K. (2021) · Current Obesity Reports · doi:10.1007/s13679-021-00458-6 · Cited by 15
Great Expectations of COVID-19 Herd Immunity
Giurgea, L. T., & Morens, D. M. (2022) · mBio · doi:10.1128/mbio.03495-21 · Cited by 15
Jalkanen, P., Kolehmainen, P., Haveri, A., Huttunen, M., Laine, L., Österlund, P., Tähtinen, P. A., Ivaska, L., Maljanen, S., Reinholm, A., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02252-21 · Cited by 15
Distinct Immune Response at 1 Year Post-COVID-19 According to Disease Severity
Kang, C. K., Kim, M., Hong, J., Kim, G., Lee, S., Chang, E., Choe, P. G., Kim, N. J., Kim, I. S., Seo, J.-Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.830433 · Cited by 16
Liu, J., Mao, Q., Wu, X., He, Q., Bian, L., Bai, Y., Wang, Z., Wang, Q., Zhang, J., Liang, Z., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.814365 · Cited by 15
Characterization and immunogenicity of SARS-CoV-2 spike proteins with varied glycosylation
Deng, T., Li, T., Chen, G., Zhu, Y., Xu, L., Lin, Y., Sun, H., Zhang, H., Fang, Q., Hong, J., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.09.057 · Cited by 16
Insight into Delta variant dominated second wave of COVID-19 in Nepal
Adhikari, K., Gautam, R. K., Pokharel, A., Dhimal, M., Uprety, K. N., & Vaidya, N. K. (2022) · Epidemics · doi:10.1016/j.epidem.2022.100642 · Cited by 15
Shen, N., Wu, Y., Chen, Y.-W., Fang, X., Zhou, M., Wang, W., Tang, M., Pan, Q.-H., Ma, J., Zhang, H., et al. (2022) · World Journal of Pediatrics · doi:10.1007/s12519-022-00621-6 · Cited by 15
Fan, F., Zhang, X., Zhang, Z., Ding, Y., Wang, L., Xu, X., Pan, Y., Gong, F., Jiang, L., Kang, L., et al. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2023.2202269 · Cited by 15
Arashiro, T., Arima, Y., Kuramochi, J., Muraoka, H., Sato, A., Chubachi, K., Yanai, A., Arioka, H., Uehara, Y., Ihara, G., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad240 · Cited by 15
Sankhala, R. S., Lal, K. G., Jensen, J. L., Dussupt, V., Mendez-Rivera, L., Bai, H., Wieczorek, L., Mayer, S. V., Zemil, M., Wagner, D. A., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44265-0 · Cited by 15
mRNA vaccines against COVID‐19: a showcase for the importance of microbial biotechnology
Brüssow, H. (2021) · Microbial Biotechnology · doi:10.1111/1751-7915.13974 · Cited by 16
Su, D., Li, X., He, C., Huang, X., Chen, M., Wang, Q., Qin, W., Liang, Y. S., Xu, R., Wu, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.16.444369 · Cited by 15
The Immunopathobiology of SARS-CoV-2 Infection
Patel, M., Shahjin, F., Cohen, J. D., Hasan, M., Machhi, J., Chugh, H., Singh, S., Das, S., Kulkarni, T. A., Herskovitz, J., et al. (2021) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuab035 · Cited by 15
Immunology of SARS-CoV-2 infections and vaccines
Schenten, D., & Bhattacharya, D. (2021) · Advances in immunology · doi:10.1016/bs.ai.2021.08.002 · Cited by 14
Motta, F. C., McGoff, K. A., Deckard, A., Wolfe, C. R., Bonsignori, M., Moody, M. A., Cavanaugh, K., Denny, T. N., Harer, J., & Haase, S. B. (2021) · JAMA Health Forum · doi:10.1001/jamahealthforum.2021.3035 · Cited by 14
COVID-19 Risk Assessment for the Tokyo Olympic Games
Zhu, W., Feng, J., Li, C., Wang, H., Zhong, Y., Zhou, L. J., Zhang, X., & Zhang, T. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.730611 · Cited by 14
Fares, N., & Lloret, J. (2022) · Journal of Global Operations and Strategic Sourcing · doi:10.1108/jgoss-09-2021-0072 · Cited by 14
Vaccination as an alternative to non-drug interventions to prevent local resurgence of COVID-19
Pan, J., Zhu, W., Tian, J., Liu, Z., Xu, A., Yao, Y., & Wang, W. (2022) · Infectious Diseases of Poverty · doi:10.1186/s40249-022-00960-6 · Cited by 14
Explaining higher Covid-19 vaccination among some US primary care professionals
Huang, Q. E., Gilkey, M. B., Thompson, P., Grabert, B. K., Dailey, S. A., & Brewer, N. T. (2022) · Social Science & Medicine · doi:10.1016/j.socscimed.2022.114935 · Cited by 15
Computation of Antigenicity Predicts SARS-CoV-2 Vaccine Breakthrough Variants
Hu, Y., Hu, J., Gong, H., Danchin, A., Sun, R., Chu, H., Hung, I. F., Yuen, K., To, K. K., Zhang, B., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.861050 · Cited by 15
Charonis, S. A., James, L. M., & Georgopoulos, A. P. (2022) · Scientific Reports · doi:10.1038/s41598-022-11956-5 · Cited by 14
Comprehensive narrative review of real-world COVID-19 vaccines: viewpoints and opportunities
Liu, S., Kang, M., Zhao, N., Zhuang, Y., Li, S., & Song, T. (2022) · Medical Review · doi:10.1515/mr-2021-0021 · Cited by 15
Personality and Motivation to Comply With COVID-19 Protective Measures in Germany
Kaspar, K., & Nordmeyer, L. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.893881 · Cited by 15
Kayabölen, A., Akcan, U., Özturan, D., Polat, H. Ü., Şahin, G. N., Degirmenci, N. P., Bayraktar, C., Söyler, G., Sarayloo, E., Nurtop, E., et al. (2022) · Advanced Science · doi:10.1002/advs.202201294 · Cited by 14
OLIVEIRA, E. A., Oliveira, M. C. L., Colosimo, E. A., Silva, A. C. S. E., MAK, R. H. K., Vasconcelos, M. A., Silva, L. R., Martelli, D. R. B., Pinhati, C. C., & Martelli‐Júnior, H. (2022) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2022.09.039 · Cited by 14
Yang, B., Huang, X., Gao, H., Leung, N., Tsang, T. K., & Cowling, B. J. (2022) · BMC Medicine · doi:10.1186/s12916-022-02600-0 · Cited by 14
COVID-19: A state of art on immunological responses, mutations, and treatment modalities in riposte
Gong, X., Khan, A., Wani, M. Y., Ahmad, A., & Duse, A. G. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.12.019 · Cited by 15
Wan, E. Y. F., Mok, A. H. Y., Yan, V. K. C., Chan, C. I. Y., Wang, B., Lai, F. T. T., Chui, C. S. L., Li, X., Wong, C. K. H., Yiu, K. H., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101195 · Cited by 14
Bsat, R., Chemaitelly, H. S., Coyle, P. V., Tang, P., Hasan, M. R., Kanaani, Z. A., Al‐Kuwari, E., Butt, A. A., Jeremijenko, A. M., Kaleeckal, A. H., et al. (2022) · Journal of Global Health · doi:10.7189/jogh.12.05004 · Cited by 14
Self-citationMor, O., Zuckerman, N. S., Hazan, I., Fluss, R., Ash, N., Ginish, N., Mendelson, E., Alroy-Preis, S., Freedman, L., & Huppert, A. (2022) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2021.10.011 · Cited by 13
Semenzato, L., Botton, J., Baricault, B., Deloumeaux, J., Joachim, C., Sylvestre, E., Dray-Spira, R., Weill, A., & Zureik, M. (2022) · PLOS ONE · doi:10.1371/journal.pone.0274309 · Cited by 13
Jahangir, M. A. (2021) · International Journal of Pharmaceutics & Pharmacology · doi:10.31531/2581-3080.1000153 · Cited by 13
An update on SARS-CoV-2 immunization and future directions
Rana, R., Kant, R., Kumra, T., Gupta, S. V., Rana, D. S., & Ganguly, N. K. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1125305 · Cited by 13
Arashiro, T., Arima, Y., Kuramochi, J., Muraoka, H., Sato, A., Chubachi, K., Oba, K., Yanai, A., Arioka, H., Uehara, Y., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.10.021 · Cited by 14
Global Trends in Ophthalmic Practices in Response to COVID-19
Tan, T., Chodosh, J., McLeod, S. D., Parke, D. W., Yeh, S., Wong, T. Y., & Ting, D. S. W. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2021.07.027 · Cited by 13
Major Insights in Dynamics of Host Response to SARS-CoV-2: Impacts and Challenges
Hakim, A., Hasan, M. M., Hasan, M., Lokman, S. M., Azim, K. F., Raihan, T., Chowdhury, P. A., & Azad, A. K. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.637554 · Cited by 13
Butt, A. A., Talisa, V. B., Peng, Y., Shaikh, O. S., Omer, S. B., & Mayr, F. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac118 · Cited by 13
Self-citationSequencing SARS-CoV-2 from antigen tests
Nazario-Toole, A., Nguyen, H. M., Xia, H., Frankel, D. N., Kieffer, J. W., & Gibbons, T. F. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263794 · Cited by 13
Epidemiology and genetic diversity of SARS-CoV-2 lineages circulating in Africa
Okoh, O. S., Nii-Trebi, N. I., Jakkari, A., Olaniran, T. T., Senbadejo, T. Y., Kafintu-kwashie, A. A., Dairo, E. O., Ganiyu, T. O., Akaninyene, I. E., Ezediuno, L. O., et al. (2022) · iScience · doi:10.1016/j.isci.2022.103880 · Cited by 13
Massonnaud, C., Roux, J., Colizza, V., & Crépey, P. (2022) · Vaccines · doi:10.3390/vaccines10030479 · Cited by 15
Megatsari, H., Kusuma, D., Ernawaty, E., & Putri, N. K. (2022) · Vaccines · doi:10.3390/vaccines10111857 · Cited by 13
BNT162b2 induces robust cross-variant SARS-CoV-2 immunity in children
Bartsch, Y. C., Chen, J. W., Kang, J., Burns, M. D., Denis, K. S., Sheehan, M. L., Davis, J. P., Edlow, A. G., Balazs, A. B., Yonker, L. M., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00575-w · Cited by 14
Patalon, T., Saciuk, Y., Hadad, H. O., Peretz, A., Peretz, A., Ben‐Tov, A., & Gazit, S. (2023) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2023.02.016 · Cited by 13
Yousif, M. G. (2023) · Research Square · doi:10.21203/rs.3.rs-3141998/v1 · Cited by 13
An Outbreak of COVID-19 among mRNA-Vaccinated Nursing Home Residents
Faggiano, F., Rossi, M. A., Cena, T., Milano, F., Barale, A., Ristagno, Q., & Silano, V. (2021) · Vaccines · doi:10.3390/vaccines9080859 · Cited by 12
SARS-CoV-2 pathophysiology and post-vaccination severity: a systematic review
Rustagi, V., Gupta, S. R. R., Talwar, C., Singh, A., Xiao, Z.-Z., Jamwal, R., Bala, K., Bhaskar, A. K., Nagar, S., & Singh, I. K. (2024) · Immunologic Research · doi:10.1007/s12026-024-09553-x · Cited by 12
Nebulised Isotonic Hydroxychloroquine Aerosols for Potential Treatment of COVID-19
Tai, W., Chow, M. Y. T., Chang, R. Y. K., Tang, P., Gonda, I., MacArthur, R. B., Chan, H., & Kwok, P. C. L. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081260 · Cited by 12
Tracking down B.1.351 SARS‐CoV‐2 variant in Pakistan through genomic surveillance
Umair, M., Ikram, A., Badar, N., Haider, S. A., Rehman, Z., Ammar, M., Ahad, A., Ali, Q., Suleman, R., & Salman, M. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27328 · Cited by 12
Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection
Psichοgiou, M., Karabinis, A., Poulakou, G., Antoniadou, A., Kotanidou, Α., Degiannis, D., Pavlopoulou, I. D., Chaidaroglou, A. S., Roussos, S., Mastrogianni, E., et al. (2021) · Vaccines · doi:10.3390/vaccines9091017 · Cited by 13
Li, M., Long, J., Wang, X., Liao, Y., Liu, Y., Hao, Y., Wu, Q., Zhou, Y., Wang, Y., Wang, Y., et al. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.782501 · Cited by 12
Perry, M., Gravenor, M. B., Cottrell, S. L., Bedston, S., Roberts, R. J., Williams, C. J., Salmon, J. E., Lyons, J., Akbari, A., Lyons, R. A., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2031774 · Cited by 12
Alali, W. Q., Ali, L. A., AlSeaidan, M., & Al-Rashidi, M. (2021) · Healthcare · doi:10.3390/healthcare9121692 · Cited by 13
Relationship between blood clots and COVID-19 vaccines: A literature review
Atyabi, S. M. H., Rommasi, F., Ramezani, M. H., Ezabadi, M. F. G., Arani, M. A., Sadeghi, M. H., Ahmed, M. M., Rajabi, A., Dehghan, N., Sohrabi, A., et al. (2022) · Open Life Sciences · doi:10.1515/biol-2022-0035 · Cited by 12
da Silva, E. S., Kohnen, M., Gilson, G., Staub, T., Arendt, V., Hilger, C., Servais, J.-Y., Charpentier, É., Domingues, O., Snoeck, C. J., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147675 · Cited by 12
Neutralizing immunity against SARS-CoV-2 Omicron BA.1 by infection and vaccination
Duan, L., Jiang, W. G., Wang, Z.-Y., Lin, Y., Zhu, K.-L., Meng, Q.-C., Wang, B., Li, L., Wang, G., & Ma, M. (2022) · iScience · doi:10.1016/j.isci.2022.104886 · Cited by 12
Helmy, S. A., Morsi, R. M. E., El-Masry, S. M., & El-Masry, S. M. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103762 · Cited by 12
SARS-CoV-2 variants of concern: a review
Sarkar, M. S., & Madabhavi, I. (2022) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2022.2337 · Cited by 14
Metadata
- Authors
- Abu-Raddad, L. J., Chemaitelly, H., & Butt, A. A.
- Affiliations
- Weill Cornell Medical College in Qatar (QA)
- Hamad Medical Corporation (QA)
- Corresponding author
- Abu-Raddad, Laith J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-07-08
- Volume
- 385
- Issue
- 2
- Pages
- 187-189
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8117967
- OpenAlex
- W3157162195
- Cited by
- 899
- References
- 4
- Citations by year
- 2026: 16 · 2025: 32 · 2024: 46 · 2023: 92 · 2022: 358 · 2021: 351
- FWCI
- 67.15
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Qatar University QSpace (Qatar University) (submittedVersion)
- Funders
- Biomedical Research Program and the Biostatistics, Epidemiology, and Biomathematics Research Core, both at Weill Cornell Medicine-Qatar, the Ministry of Public Health and Hamad Medical Corporation
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Keywords
- BNT162b2, COVID-19 vaccine efficacy, SARS-CoV-2 variants, B.1.1.7 variant, B.1.351 variant, Omicron variant, vaccination campaigns, viral genome sequencing, COVID-19 waves
- MeSH terms
- Immunogenicity, Vaccine, COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, Humans, Qatar, Cohort Studies, Case-Control Studies, Polymerase Chain Reaction, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
